中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The RAMP Study - Rejuvenation of the Aging Microbiota With Prebiotics

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态主动,不招募
赞助商
Stanford University
合作者
Abbott

关键词

抽象

An individual's immune and metabolic status is coupled to consumed carbohydrates. Complex carbohydrates that are not digested by human enzymes may influence host biology by impacting microbiota composition and function, or act in a yet-unknown microbiota-independent manner. Prebiotics offer a promising safe route to influence host health, possibly via the microbiota. However, it remains largely unknown to what extent immune function and metabolism can be modulated by prebiotics.

描述

The objective of this study is to define the impact of a prebiotic supplement on microbiome, immune system, and metabolic status in older adults. This study will determine the degree to which a prebiotic supplement can 1) regulate immune status and function including reducing chronic, systemic inflammation as assessed by high dimensional immune profiling, 2) alter microbiota composition and function, 3) impact the microbiota metabolites—potential normalizers of metabolic and immune dysfunction, and 4) alter metabolic markers.

日期

最后验证: 04/30/2020
首次提交: 09/16/2018
提交的预估入学人数: 09/27/2018
首次发布: 09/30/2018
上次提交的更新: 05/06/2020
最近更新发布: 05/10/2020
实际学习开始日期: 03/13/2019
预计主要完成日期: 11/30/2020
预计完成日期: 11/30/2020

状况或疾病

Microbiome
Immune Function
Inflammation

干预/治疗

Dietary Supplement: Placebo group

Dietary Supplement: Prebiotic supplement

-

手臂组

干预/治疗
Placebo Comparator: Placebo group
Placebo product
Dietary Supplement: Placebo group
Placebo product
Experimental: Prebiotic Supplement, low dose
Experimental: Prebiotic Supplement, high dose

资格标准

有资格学习的年龄 60 Years 至 60 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- 60 years old and older

- Otherwise, healthy subjects willing and able to provide blood as well as stool specimens

- Must be able to provide signed and dated informed consent and be willing to follow protocol

Exclusion Criteria:

- Body Mass Index >= 40

- LDL-C > 190 mg/dL

- Systolic Blood Pressure >160 mmHg OR Diastolic Blood Pressure > 90 mmHg

- Use of any of the following drugs/supplements within the last 2 months:

- systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral);

- corticosteroids (intravenous, intramuscular, oral, nasal or inhaled)

- cytokines

- methotrexate or immunosuppressive cytotoxic agents

- metformin

- proton pump inhibitors (PPIs)

- Regular use of any of the following medications:

- regular dose aspirin (>81mg/day)

- opiate pain medication

- Use of large doses of commercial probiotics consumed (greater than or equal to 10-8 cfu or organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply.

- Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Examples include flu or gastroenteritis. Defer sampling until subject recover.

- Chronic, clinically significant, unstable (unresolved, requiring on-going changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history. Type 2 diabetes, type 1 diabetes, and dialysis will be excluded.

- History of active uncontrolled gastrointestinal disorders or diseases including:

- inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;

- irritable bowel syndrome (IBS) (moderate-severe);

- persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated).

- History of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.

- Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.

- Recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or > 14 drinks/week.

- Positive test for HIV, HBV or HCV.

- Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection.

- Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.

- Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products.

- Any confirmed or suspected autoimmune disease. Examples include multiple sclerosis and Graves disease.

- Veganism.

- Dairy allergies.

结果

主要结果指标

1. Immune status and function [Baseline and 6 weeks]

Change from baseline in Cytokine Response Score (CRS) at 6 weeks. The CRS is a single composite measure of cell-type specific activation of signaling pathways from ex vivo cytokine stimulation of blood samples. This provides a measure of immune response capacity which may be an indicator of immune fitness. The CRS will be calculated as described in Shen-Orr et al, Cell Systems, 2016. The CRS is the sum of 15 age-associated normalized cytokine responses identified in Shen-Orr et. al: In CD8+ T cells: IFNα pSTAT1, pSTAT3, pSTAT5; IL-6 pSTAT1, pSTAT3, pSTAT5; IFNγ pSTAT1; IL-21 pSTAT1; In CD4+ T cells: IFNα pSTAT5; IL-6 pSTAT5; In B cells: IFNα pSTAT1; in monocytes: IL-10 pSTAT3; IFNγ pSTAT3; IFNα pSTAT3; IL-6 pSTAT3. Each feature is calculated as the fold change of the protein in the stimulated condition relative to its level in the unstimulated condition. That value is then normalized to the feature's range: normalized = (x - xmin)/xmax. The 15 normalized values are summed for the CRS.

次要成果指标

1. Microbiota composition [Baseline and 6 weeks]

Change from baseline in alpha diversity at 6 weeks. We will be using number of observed sequence variants ("species") determined by standard 16S rRNA amplicon sequencing (V3-V5 region followed by DADA2 to define error-corrected sequence variants) as our primary metric of alpha diversity. Higher alpha diversity is better. The units are the # of sequence variants.

2. Microbiota function [Baseline and 6 weeks]

Change from baseline in composite of short-chain fatty acids (SCFA) concentration (ug/g stool: acetate + propionate + butyrate) at 6 weeks.

3. Weight [Baseline and 6 weeks]

Change from Baseline in weight at 6 weeks.

4. Waist Circumference [Baseline and 6 weeks]

Change from Baseline in waist circumference at 6 weeks.

5. Blood pressure [Baseline and 6 weeks]

Change from Baseline in blood pressure at 6 weeks.

6. Total Cholesterol [Baseline and 6 weeks]

Change from Baseline in total cholesterol at 6 weeks.

7. Triglycerides [Baseline and 6 weeks]

Change from Baseline in triglycerides at 6 weeks.

8. HDL-cholesterol [Baseline and 6 weeks]

Change from Baseline in HDL-cholesterol at 6 weeks.

9. Fasting Glucose [Baseline and 6 weeks]

Change from Baseline in fasting glucose at 6 weeks.

10. Fasting Insulin [Baseline and 6 weeks]

Change from Baseline in fasting insulin at 6 weeks.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge